Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “ALK+ Non-Small-Cell Lung Carcinoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT06362369
What this trial is testing

Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

Who this might be right for
Advanced CancerAdvanced Solid TumorMelanoma+15 more
7 Hills Pharma, LLC 126
Not applicableStudy completedNCT03944265
What this trial is testing

Genetics and Shared Decision Making in Improving Care for Patients With Stage IVA-C Non-small Cell Lung Cancer

Who this might be right for
Activating ALK Gene Mutation NegativeActivating EGFR Gene Mutation NegativeActivating ROS1 Gene Mutation Negative+5 more
Thomas Jefferson University 14
Testing effectiveness (Phase 2)Ended earlyNCT02521051
What this trial is testing

Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer (NSCLC)
Massachusetts General Hospital 11
Post-approval studies (Phase 4)Active Not RecruitingNCT05160922
What this trial is testing

Crizotinib Continuation Clinical Study

Who this might be right for
NSCLCALCLIMT
Pfizer 27
Post-approval studies (Phase 4)Study completedNCT04541706
What this trial is testing

Lorlatinib in ALK Inhibitor Treated Unresectable Advanced/Recurrent ALK-Positive Non Small Cell Lung Cancer Patients in India

Who this might be right for
Advanced Non-Small Cell Lung Cancer
Pfizer 100
Large-scale testing (Phase 3)UnknownNCT05204628
What this trial is testing

Evaluate and Compare the Efficacy and Safety of XZP-3621 Versus Crizotinib

Who this might be right for
Non-small Cell Lung Cancer
Xuanzhu Biopharmaceutical Co., Ltd. 238
Not applicableUnknownNCT06207292
What this trial is testing

Stereotactic Ablative Radiotherapy in Synchronous and Metachronous Oligo-Metastatic Non Small Cell Lung Cancer

Who this might be right for
NSCLCNSCLC Stage IVOligometastatic Disease+9 more
Radiotherapy Oncology Centre "Santa Maria" Hospital 100
Testing effectiveness (Phase 2)Study completedNCT00932451
What this trial is testing

An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Pfizer 1,069
Post-approval studies (Phase 4)Not Yet RecruitingNCT07671560
What this trial is testing

Efficacy and Safety of Ensartinib Combined With Anlotinib in Lorlatinib-Resistant ALK-Positive NSCLC

Who this might be right for
ALK-positive, Locally Advanced or Metastatic (TNM Stage IIIB-IV) Non-small Cell Lung Cancer That Has Developed Resistance to Prior Treatment With Lorlatinib
Qiming Wang 80
Testing effectiveness (Phase 2)WithdrawnNCT05718297
What this trial is testing

Brigatinib Post Definitive Chemo-radiotherapy in Patients with ALK-fusion Non-small Cell Lung Cancer

Who this might be right for
NSCLC, Stage IIIALK-rearrangement
ETOP IBCSG Partners Foundation
Testing effectiveness (Phase 2)Study completedNCT03909971
What this trial is testing

Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Pfizer 109
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07771764
What this trial is testing

Exploratory Clinical Study of Iruplaltinib Combined With Pemetrexed as Neoadjuvant Therapy for Resectable ALK-Positive Non-Squamous Non-Small Cell Lung Cancer

Who this might be right for
ALK-positive Non Small Cell Lung Cancer
First Affiliated Hospital of Fujian Medical University 30
Testing effectiveness (Phase 2)WithdrawnNCT01500824
What this trial is testing

A Clinical Study Testing The Safety And Efficacy Of Crizotinib In East Asian Patients With Anaplastic Lymphoma Kinase (ALK) Positive Advanced Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Pfizer
Not applicableUnknownNCT06234579
What this trial is testing

Longitudinal Assessment of Genomic Alterations and Clonal Evolution in ALK-positive NSCLC (Galileo Project)

Who this might be right for
ALK Gene MutationNSCLC Stage IVALK Sensitizing Mutation
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 108
Early research (Phase 1)Study completedNCT02442414
What this trial is testing

KBP-5209 in Patients With Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumors
Sihuan Pharmaceutical Holdings Group Ltd. 35
Early research (Phase 1)Study completedNCT02259114
What this trial is testing

A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003)

Who this might be right for
NUT Midline CarcinomaTriple Negative Breast CancerNon-small Cell Lung Cancer With Rearranged ALK Gene/Fusion Protein or KRAS Mutation+3 more
Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) 47
Testing effectiveness (Phase 2)UnknownNCT05675033
What this trial is testing

Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung Adenocarcinoma

Who this might be right for
Lung AdenocarcinomaStage IV Non-small Cell Lung CancerPD-1 Inhibitor+1 more
Fujian Cancer Hospital 50
Testing effectiveness (Phase 2)Study completedNCT03410108
What this trial is testing

Phase 2 Study of Brigatinib in Japanese Participants With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
ALK-positive Advanced NSCLC
Takeda 104
Not applicableLooking for participantsNCT04900935
What this trial is testing

Patient-centered, Optimal Integration of Survivorship and Palliative Care

Who this might be right for
Stage IV Non-small Cell Lung CancerTargeted TherapyNonsmall Cell Lung Cancer+5 more
Massachusetts General Hospital 70
Post-approval studies (Phase 4)Active Not RecruitingNCT06282874
What this trial is testing

Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases

Who this might be right for
Carcinoma, Non-Small-Cell LungBrain MetastasesLeptomeningeal Metastasis
Guangdong Association of Clinical Trials 41
Next Page